Circulating free mitochondrial DNA concentration and its association with erlotinib treatment in patients with adenocarcinoma of the lung

Chu Yun Huang, Yuh Min Chen, Chieh Hung Wu, Chun Ming Tsai, Yu Chin Lee, Reury Perng Perng, Jacqueline Whang-Peng

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Changes in circulating free DNA concentrations have been correlated with chemotherapeutic effects in solid tumors. The present study was designed to determine and compare the changes in circulating free mitochondrial DNA (mtDNA) concentrations prior to and following erlotinib treatment, as well as the potential prognostic value of plasma mtDNA. Patients with adenocarcinoma of the lung who were to receive erlotinib treatment were enrolled in the present study once informed consent had been obtained. Patient plasma samples were collected immediately prior to starting erlotinib treatment, on days 15 and 29 following the initiation of erlotinib treatment and also when the patient's disease had progressed. The most common erlotinib treatment response was a partial response (PR), achieved in 26 (49.1%) of the 53 enrolled patients, followed by stable disease (SD) in 13 patients (24.5%) and progressive disease (PD) in 14 patients (26.4%). Plasma mtDNA concentrations were significantly decreased on day 15 compared with day 0 in the patients with PD (P=0.028) or in those patients without a response to erlotinib treatment (SD and PD; P=0.007). Plasma mtDNA concentrations were similar or elevated on day 15 compared with day 0 in the patients with a PR (P=0.808). The concentration of plasma mtDNA did not correlate with progression-free survival (PFS). Tumor epidermal growth factor receptor (EGFR) mutation status (activating mutations in 16 patients and wild-type in 14 patients) did not correlate with the concentration of plasma mtDNA (P=0.951). Plasma mtDNA levels did not correlate with the PFS of the patients when they received erlotinib treatment. The plasma mtDNA levels were decreased on day 15 in those patients who had disease progression following erlotinib treatment. These results demonstrate that plasma mtDNA is of weak clinical utility as a screening, diagnostic or prognostic tool in lung cancer patients.

Original languageEnglish
Pages (from-to)2180-2184
Number of pages5
JournalOncology Letters
Volume7
Issue number6
DOIs
Publication statusPublished - Jan 1 2014

Fingerprint

Mitochondrial DNA
Therapeutics
Adenocarcinoma of lung
Erlotinib Hydrochloride
Disease-Free Survival
Mutation
Informed Consent
Epidermal Growth Factor Receptor
Disease Progression
Lung Neoplasms
Neoplasms

Keywords

  • Epidermal growth factor receptor
  • Lung cancer
  • Mitochondria
  • Tyrosine kinase inhibitor

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Circulating free mitochondrial DNA concentration and its association with erlotinib treatment in patients with adenocarcinoma of the lung. / Huang, Chu Yun; Chen, Yuh Min; Wu, Chieh Hung; Tsai, Chun Ming; Lee, Yu Chin; Perng, Reury Perng; Whang-Peng, Jacqueline.

In: Oncology Letters, Vol. 7, No. 6, 01.01.2014, p. 2180-2184.

Research output: Contribution to journalArticle

Huang, Chu Yun ; Chen, Yuh Min ; Wu, Chieh Hung ; Tsai, Chun Ming ; Lee, Yu Chin ; Perng, Reury Perng ; Whang-Peng, Jacqueline. / Circulating free mitochondrial DNA concentration and its association with erlotinib treatment in patients with adenocarcinoma of the lung. In: Oncology Letters. 2014 ; Vol. 7, No. 6. pp. 2180-2184.
@article{d42c81cc9e434f4fbcb2f3984b7e7ab4,
title = "Circulating free mitochondrial DNA concentration and its association with erlotinib treatment in patients with adenocarcinoma of the lung",
abstract = "Changes in circulating free DNA concentrations have been correlated with chemotherapeutic effects in solid tumors. The present study was designed to determine and compare the changes in circulating free mitochondrial DNA (mtDNA) concentrations prior to and following erlotinib treatment, as well as the potential prognostic value of plasma mtDNA. Patients with adenocarcinoma of the lung who were to receive erlotinib treatment were enrolled in the present study once informed consent had been obtained. Patient plasma samples were collected immediately prior to starting erlotinib treatment, on days 15 and 29 following the initiation of erlotinib treatment and also when the patient's disease had progressed. The most common erlotinib treatment response was a partial response (PR), achieved in 26 (49.1{\%}) of the 53 enrolled patients, followed by stable disease (SD) in 13 patients (24.5{\%}) and progressive disease (PD) in 14 patients (26.4{\%}). Plasma mtDNA concentrations were significantly decreased on day 15 compared with day 0 in the patients with PD (P=0.028) or in those patients without a response to erlotinib treatment (SD and PD; P=0.007). Plasma mtDNA concentrations were similar or elevated on day 15 compared with day 0 in the patients with a PR (P=0.808). The concentration of plasma mtDNA did not correlate with progression-free survival (PFS). Tumor epidermal growth factor receptor (EGFR) mutation status (activating mutations in 16 patients and wild-type in 14 patients) did not correlate with the concentration of plasma mtDNA (P=0.951). Plasma mtDNA levels did not correlate with the PFS of the patients when they received erlotinib treatment. The plasma mtDNA levels were decreased on day 15 in those patients who had disease progression following erlotinib treatment. These results demonstrate that plasma mtDNA is of weak clinical utility as a screening, diagnostic or prognostic tool in lung cancer patients.",
keywords = "Epidermal growth factor receptor, Lung cancer, Mitochondria, Tyrosine kinase inhibitor",
author = "Huang, {Chu Yun} and Chen, {Yuh Min} and Wu, {Chieh Hung} and Tsai, {Chun Ming} and Lee, {Yu Chin} and Perng, {Reury Perng} and Jacqueline Whang-Peng",
year = "2014",
month = "1",
day = "1",
doi = "10.3892/ol.2014.2006",
language = "English",
volume = "7",
pages = "2180--2184",
journal = "Oncology Letters",
issn = "1792-1074",
publisher = "Spandidos Publications",
number = "6",

}

TY - JOUR

T1 - Circulating free mitochondrial DNA concentration and its association with erlotinib treatment in patients with adenocarcinoma of the lung

AU - Huang, Chu Yun

AU - Chen, Yuh Min

AU - Wu, Chieh Hung

AU - Tsai, Chun Ming

AU - Lee, Yu Chin

AU - Perng, Reury Perng

AU - Whang-Peng, Jacqueline

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Changes in circulating free DNA concentrations have been correlated with chemotherapeutic effects in solid tumors. The present study was designed to determine and compare the changes in circulating free mitochondrial DNA (mtDNA) concentrations prior to and following erlotinib treatment, as well as the potential prognostic value of plasma mtDNA. Patients with adenocarcinoma of the lung who were to receive erlotinib treatment were enrolled in the present study once informed consent had been obtained. Patient plasma samples were collected immediately prior to starting erlotinib treatment, on days 15 and 29 following the initiation of erlotinib treatment and also when the patient's disease had progressed. The most common erlotinib treatment response was a partial response (PR), achieved in 26 (49.1%) of the 53 enrolled patients, followed by stable disease (SD) in 13 patients (24.5%) and progressive disease (PD) in 14 patients (26.4%). Plasma mtDNA concentrations were significantly decreased on day 15 compared with day 0 in the patients with PD (P=0.028) or in those patients without a response to erlotinib treatment (SD and PD; P=0.007). Plasma mtDNA concentrations were similar or elevated on day 15 compared with day 0 in the patients with a PR (P=0.808). The concentration of plasma mtDNA did not correlate with progression-free survival (PFS). Tumor epidermal growth factor receptor (EGFR) mutation status (activating mutations in 16 patients and wild-type in 14 patients) did not correlate with the concentration of plasma mtDNA (P=0.951). Plasma mtDNA levels did not correlate with the PFS of the patients when they received erlotinib treatment. The plasma mtDNA levels were decreased on day 15 in those patients who had disease progression following erlotinib treatment. These results demonstrate that plasma mtDNA is of weak clinical utility as a screening, diagnostic or prognostic tool in lung cancer patients.

AB - Changes in circulating free DNA concentrations have been correlated with chemotherapeutic effects in solid tumors. The present study was designed to determine and compare the changes in circulating free mitochondrial DNA (mtDNA) concentrations prior to and following erlotinib treatment, as well as the potential prognostic value of plasma mtDNA. Patients with adenocarcinoma of the lung who were to receive erlotinib treatment were enrolled in the present study once informed consent had been obtained. Patient plasma samples were collected immediately prior to starting erlotinib treatment, on days 15 and 29 following the initiation of erlotinib treatment and also when the patient's disease had progressed. The most common erlotinib treatment response was a partial response (PR), achieved in 26 (49.1%) of the 53 enrolled patients, followed by stable disease (SD) in 13 patients (24.5%) and progressive disease (PD) in 14 patients (26.4%). Plasma mtDNA concentrations were significantly decreased on day 15 compared with day 0 in the patients with PD (P=0.028) or in those patients without a response to erlotinib treatment (SD and PD; P=0.007). Plasma mtDNA concentrations were similar or elevated on day 15 compared with day 0 in the patients with a PR (P=0.808). The concentration of plasma mtDNA did not correlate with progression-free survival (PFS). Tumor epidermal growth factor receptor (EGFR) mutation status (activating mutations in 16 patients and wild-type in 14 patients) did not correlate with the concentration of plasma mtDNA (P=0.951). Plasma mtDNA levels did not correlate with the PFS of the patients when they received erlotinib treatment. The plasma mtDNA levels were decreased on day 15 in those patients who had disease progression following erlotinib treatment. These results demonstrate that plasma mtDNA is of weak clinical utility as a screening, diagnostic or prognostic tool in lung cancer patients.

KW - Epidermal growth factor receptor

KW - Lung cancer

KW - Mitochondria

KW - Tyrosine kinase inhibitor

UR - http://www.scopus.com/inward/record.url?scp=84898874460&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84898874460&partnerID=8YFLogxK

U2 - 10.3892/ol.2014.2006

DO - 10.3892/ol.2014.2006

M3 - Article

AN - SCOPUS:84898874460

VL - 7

SP - 2180

EP - 2184

JO - Oncology Letters

JF - Oncology Letters

SN - 1792-1074

IS - 6

ER -